STAAR Surgical (NASDAQ:STAA) CEO Caren L. Mason sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $36.25, for a total value of $271,875.00. Following the completion of the sale, the chief executive officer now directly owns 44,013 shares in the company, valued at $1,595,471.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
NASDAQ STAA traded down $1.73 during mid-day trading on Friday, reaching $37.67. The stock had a trading volume of 387,483 shares, compared to its average volume of 391,960. STAAR Surgical has a 1 year low of $13.60 and a 1 year high of $54.00. The firm has a market cap of $1.74 billion, a P/E ratio of 134.64 and a beta of 2.11.
STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Thursday, February 21st. The medical instruments supplier reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. STAAR Surgical had a net margin of 4.01% and a return on equity of 13.86%. The company had revenue of $31.19 million during the quarter, compared to analyst estimates of $31.20 million. Equities research analysts predict that STAAR Surgical will post 0.3 earnings per share for the current year.
STAA has been the topic of a number of analyst reports. BidaskClub raised STAAR Surgical from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. ValuEngine cut STAAR Surgical from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 21st. TheStreet cut STAAR Surgical from a “b-” rating to a “c” rating in a research report on Friday, December 14th. Finally, Zacks Investment Research cut STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, March 2nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.25.
TRADEMARK VIOLATION WARNING: “Caren L. Mason Sells 7,500 Shares of STAAR Surgical (STAA) Stock” was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2019/03/22/caren-l-mason-sells-7500-shares-of-staar-surgical-staa-stock.html.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.